Interestingly, a previous study of cell replacement therapy in a model of amyotrophic lateral sclerosis (ALS) using a treatment of NOX2-deficient monocytes ameliorated microglia activation leading to extended animal survival in ALS (Chiot et al., 2020). This evidence concerns the gene CYBB and amyotrophic lateral sclerosis.